Carregant...
Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention
INTRODUCTION: Clopidogrel is commonly prescribed with aspirin to reduce the risk for adverse cardiovascular events after percutaneous coronary intervention (PCI). However, there is significant inter-patient variability in clopidogrel response. The CYP2C19 enzyme is involved in the biotransformation...
Guardat en:
| Publicat a: | Expert Rev Cardiovasc Ther |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5628391/ https://ncbi.nlm.nih.gov/pubmed/28699807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14779072.2017.1355236 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|